- Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases
-
Limsrivilai J, Pausawasdi N
- KMID: 2512098
- Intest Res.
- 2021 Jan;19(1):21-32.
- doi: 10.5217/ir.2019.09142
Differentiating Crohn’s disease (CD) from intestinal tuberculosis (ITB) is a diagnostic dilemma, particularly in regions where ITB is prevalent and CD incidence is increasing, because both diseases can present quite... -
- CITED
-
- Close
- SHARE
-
- Close
- Endoscopic molecular imaging in inflammatory bowel disease
-
Ham NS, Myung SJ
- KMID: 2512099
- Intest Res.
- 2021 Jan;19(1):33-44.
- doi: 10.5217/ir.2019.09175
Molecular imaging is a technique for imaging the processes occurring in a living body at a molecular level in real-time, combining molecular cell biology with advanced imaging technologies using molecular... -
- CITED
-
- Close
- SHARE
-
- Close
- Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
-
Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2512107
- Intest Res.
- 2021 Jan;19(1):115-118.
- doi: 10.5217/ir.2020.00030
-
- CITED
-
- Close
- SHARE
-
- Close
- Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment
-
Akiyama S, Rai V, Rubin DT
- KMID: 2512096
- Intest Res.
- 2021 Jan;19(1):1-11.
- doi: 10.5217/ir.2020.00047
Patients with inflammatory bowel disease (IBD) occasionally need a restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) because of medically refractory colitis or dysplasia/cancer. However, pouchitis may develop in up to... -
- CITED
-
- Close
- SHARE
-
- Close
- Two intertwined compartments coexisting in sporadic conventional colon adenomas
-
Rubio CA
- KMID: 2512097
- Intest Res.
- 2021 Jan;19(1):12-20.
- doi: 10.5217/ir.2019.00133
Sporadic conventional colon adenomas are microscopically built of 2 intertwined compartments: one on top, harboring the dysplastic tissue that defines their histo-biomolecular attributes, and the other below, composed of non-dysplastic... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
-
Jeong Y, Jeon SR, Kim HG, Moon JR, Lee TH, Jang JY, Cho JH, Park JS, Park H, Lee Kh, Kim JO, Lee JS, Ko BM, Park S
- KMID: 2512102
- Intest Res.
- 2021 Jan;19(1):62-70.
- doi: 10.5217/ir.2019.09156
Background/Aims: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can serve as biomarkers for diagnosing and assessing disease activity in ulcerative colitis (UC). We investigated their clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Whipple disease mimicking inflammatory bowel disease
-
Tatsuki M, Ishige T, Igarashi Y, Hatori R, Hokama A, Hirato J, Muise A, Takizawa T, Arakawa H
- KMID: 2512108
- Intest Res.
- 2021 Jan;19(1):119-125.
- doi: 10.5217/ir.2019.09177
Whipple disease is a systemic chronic infection caused by Tropheryma whipplei. Although chronic diarrhea is a common gastrointestinal symptom, diagnosis is often difficult because there are no specific endoscopic findings,... -
- CITED
-
- Close
- SHARE
-
- Close
- Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver
-
Agarwal A, Singh A, Mehtab W, Gupta V, Chauhan A, Rajput MS, Singh N, Ahuja V, Makharia GK
- KMID: 2512106
- Intest Res.
- 2021 Jan;19(1):106-114.
- doi: 10.5217/ir.2019.00136
Background/Aims: Gluten-free diet has an excess of fats and simple sugars and puts patients with celiac disease at risk of metabolic complications including metabolic syndrome and fatty liver. We assessed... -
- CITED
-
- Close
- SHARE
-
- Close
- Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
-
Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T
- KMID: 2512105
- Intest Res.
- 2021 Jan;19(1):95-105.
- doi: 10.5217/ir.2019.09167
Background/Aims: Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance... -
- CITED
-
- Close
- SHARE
-
- Close
- Quality of life in inflammatory bowel diseases: it is not all about the bowel
-
Keller R, Mazurak N, Fantasia L, Fusco S, Malek NP, Wehkamp J, Enck P, Klag T
- KMID: 2512100
- Intest Res.
- 2021 Jan;19(1):45-52.
- doi: 10.5217/ir.2019.00135
Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
-
Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H
- KMID: 2512101
- Intest Res.
- 2021 Jan;19(1):53-61.
- doi: 10.5217/ir.2019.09146
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
-
Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S
- KMID: 2512103
- Intest Res.
- 2021 Jan;19(1):71-82.
- doi: 10.5217/ir.2019.09159
Background/Aims: The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
-
Banerjee R, Chuah SW, Hilmi IN, Wu DC, Yang SK, Demuth D, Lindner D, Adsul S
- KMID: 2512104
- Intest Res.
- 2021 Jan;19(1):83-94.
- doi: 10.5217/ir.2019.09160
Background/Aims: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
